Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A chemotherapy combination regimen consisting of cyclophosphamide, doxorubicin (also known as Adriamycin), and paclitaxel. This regimen is typically administered sequentially, with cyclophosphamide and doxorubicin (AC) given first, followed by paclitaxel. It is primarily used in the treatment of breast cancer in both adjuvant and neoadjuvant settings. The regimen can be administered in standard 3-week cycles or dose-dense 2-week cycles with growth factor support.
- Brand names
- AdriamycinCytoxanTaxol
- Other names
- AC-paclitaxelAC followed by paclitaxelAC-T
02
Targets
TOP2A (DNA topoisomerase II)MicrotubuleDNA
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + paclitaxel.